Fortress Biotech Announces Final Patient Dosed in Phase 1B Trial of CAEL-101 for the Treatment of AL Amyloidosis May 04, 2017
Mustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer Apr 24, 2017
Fortress Biotech to Present at BioCentury’s 24th Annual Future Leaders in the Biotech Industry Conference Mar 30, 2017
Checkpoint Therapeutics to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2017 Mar 20, 2017
Fortress Biotech Reports Financial Results for the Fourth Quarter and Full Year Ended December 31, 2016 Mar 16, 2017
Fortress Biotech Forms New Subsidiary, Cyprium Therapeutics, Inc., to Develop Novel Therapies for Menkes Disease and Related Copper Metabolism Disorders Mar 14, 2017
